Endpoints
The European Committee on Antimicrobial Susceptibility Testing (EUCAST)
determined 2 µg/mL of meropenem as a susceptible breakpoint of meropenem
for the Gram-negative organisms (MIC). The primary pharmacodynamic
endpoint of this study was the concentrations above the breakpoints for
≥50% of the dosing interval (ft>MIC ≥ 50%), and the
secondary endpoint was ft>MIC= 100%.